Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Fotobiomoduleringsprotokoll i analgesi av kemoterapi-inducerad oral mukosit hos barn (CURALASE01)

2 november 2026 uppdaterad av: University Hospital, Toulouse

Dubbelblind, randomiserad, multicenter, icke-underlägsenhet klinisk prövning som jämför två fotobiomoduleringsprotokoll i analgesi av kemoterapi-inducerad oral mukosit hos barn

Chemotherapy-induced oropharyngeal mucositis (OM) negatively impacts the quality of life of adult and pediatric patients by causing pain, dysphagia, dysgeusia and dysphonia.

Photobiomodulation (PBM) by low level laser therapy (LLLT), light therapy of low level of red and infrared wavelengths (630-1000 nm) has been recommended since 2014 in patients treated with high-dose chemotherapy for bone marrow transplantation. Available pediatric studies highlighted positive/promising results of PBM with excellent safety and no adverse effects. Nevertheless, a wide variety of application parameters is described in the literature, with no consensus guidelines.

Considering the lack of standardized protocol of photobiomodulation in the pediatric population as well as the burden and cost of a daily application, investigators have decided to conduct, for the first time in children of 3 years of age or older, a multicenter, randomized, double-blind, non-inferiority clinical trial to compare two PBM protocols with same PBM parameters, combining red and infrared wavelengths, but with different frequencies of laser application (daily versus every other day), in the treatment of chemotherapy-induced OM of WHO grade 2 or higher.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

87

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Angers, Frankrike
        • University hospital of Angers
      • Besançon, Frankrike
        • University hospital of Besançon
      • Grenoble, Frankrike
        • University hospital of Grenoble
      • Lille, Frankrike
        • University hospital of Lille
      • Limoges, Frankrike
        • University hospital of Limoges
      • Marseille, Frankrike
        • Hôpital La Timone
      • Nancy, Frankrike
        • University hospital of Nancy
      • Nice, Frankrike
        • University Hospital of Nice
      • Paris, Frankrike
        • Armand Trousseau Hospital
      • Poitiers, Frankrike
        • University hospital of Poitiers
      • Reims, Frankrike
        • University hospital of Reims
      • Rouen, Frankrike
        • University hospital of Rouen
      • Saint-Etienne, Frankrike
        • University hospital of Saint-Etienne
      • Strasbourg, Frankrike
        • University hospital of Strasbourg
      • Tours, Frankrike
        • University Hospital of Tours
    • Occitanie
      • Toulouse, Occitanie, Frankrike, 31000
        • University hospital of Toulouse

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

3 år till 17 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Male or female children aged ≥ 3 years and < 18 years.
  2. Hospitalization in an oncology or hematology department in the participating centres.
  3. Patients with oropharyngeal mucositis of grade 2 or higher (WHO grading system) related to cancer chemotherapy, including conditioning for Hematopoietic Stem Cell Transplantation (HSCT).
  4. Written informed consent of both patient's holders of parental authority, and patient's assent when applicable.
  5. Patients affiliated to a French Social Security insurance or equivalent social protection.
  6. Absence of any physical or psychological disability that may interfere with the LLLT application.

Exclusion Criteria:

  1. Patients with a solid cancer lesion in the area of low-level laser application.
  2. History of cervicofacial radiotherapy.
  3. Application of low-level laser therapy for oral mucositis within 2 weeks prior to randomization.
  4. Hyperthyroidism defined by TSH < 0.4 IU/mL at inclusion.
  5. Patients susceptible to epilepsy seizure.
  6. Patients with pacemaker.
  7. Patients refusing to wear retinal goggles during low-level laser 1. Patients with a solid cancer lesion in the area of low-level laser application.
  8. Patients protected by law (guardianship and safeguarding of justice).
  9. Pregnant female patients as determined by positive serum pregnancy test at screening.
  10. Lactating female patients who are actively breast feeding.
  11. Participation in another clinical trial involving oral care.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: LLLT applied every other day

Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day

Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day

Aktiv komparator: LLLT applied daily

Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day

Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Session evaluation
Tidsram: Throught treatment period up to 1 month

Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application)

Throught treatment period up to 1 month

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Production costs evaluation
Tidsram: 2 months

Production costs from the hospital perspective and efficacy (i.e. number of days after which a child has no longer mucositis related pain as described in the primary endpoint section) to build Incremental Cost-Effectiveness Ratio (ICER) comparing every other day LLLT application versus with daily LLLT application.

2 months
Health insurance evaluation
Tidsram: 2 months

Costs of inpatient hospital stays from the French health insurance perspective.

2 months
OM duration evaluation
Tidsram: Throught treatment period up to 1 month

Duration (in days) of chemotherapy-induced OM of WHO grade 2 or higher between the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM at 2 consecutive measurements before the next scheduled PBM session (either every other day application or daily application).

Throught treatment period up to 1 month
OM occurrence
Tidsram: 2 months

Occurrence of chemotherapy-induced OM of WHO grade 3 or 4 (deterioration of the clinical situation).

2 months
Feed evaluation
Tidsram: 2 months

Occurrence of enteral feeding.

2 months
Analgesic consumption
Tidsram: 2 months

Duration (in days) of consumption of step 2 and step 3 analgesics during chemotherapy-induced OM of WHO grade 2 or higher.

2 months
PBM evaluation
Tidsram: Through treatment period up to 1 month

Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) as evaluated, regardless of patient's age, with the ChIMES scale and use of step 3 analgesics.

Through treatment period up to 1 month
Pain change evaluation
Tidsram: From baseline to each day of PBM session

Change over time in WHO grade 2 or higher chemotherapy-induced OM related pain, as assessed by pain scales (HEDEN (Hétero Evaluation Douleur Enfant) mucositis scale (5 items ranging from 0 to 2) or VAS (ranging from 0 to 10)depending on patient's age category, and Children's International Mucositis Evaluation Scale (4 items ranging from 0 to 5) whatever patient's age category)

From baseline to each day of PBM session
Adverse events occurrence
Tidsram: 2 months

Occurrence of adverse events reported according to descriptions and grading scale found in NCI CTCAE version 5.0.

2 months
thyroid-stimulating hormone (TSH) evolution
Tidsram: From baseline to 2 months

TSH shift from baseline value classified according to the following three categories: "< 0.4 IU/mL", "[0.4 - 10] IU/mL", "> 10 IU/mL", to value at D14-31 after end of WHO grade 2 or higher chemotherapy-induced OM classified according to the same three categories.

From baseline to 2 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Marlène PASQUET, University Hospital, Toulouse

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 maj 2021

Primärt slutförande (Faktisk)

22 maj 2024

Avslutad studie (Faktisk)

22 maj 2024

Studieregistreringsdatum

Först inskickad

4 september 2020

Först inskickad som uppfyllde QC-kriterierna

15 oktober 2020

Första postat (Faktisk)

22 oktober 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • RC31/19/0556

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera